Osmotica Pharmaceuticals plc - Ordinary Shares (OSMT): Price and Financial Metrics
Osmotica Pharmaceuticals plc - Ordinary Shares (OSMT)
Today's Latest Price: $4.38 USD
Updated Jan 25 8:20am
Add OSMT to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
OSMT Stock Summary
- OSMT's went public 2.27 years ago, making it older than just 5.04% of listed US stocks we're tracking.
- With a year-over-year growth in debt of -18.71%, Osmotica Pharmaceuticals plc's debt growth rate surpasses merely 15.84% of about US stocks.
- Revenue growth over the past 12 months for Osmotica Pharmaceuticals plc comes in at -17.31%, a number that bests just 20.85% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Osmotica Pharmaceuticals plc, a group of peers worth examining would be ORBC, LIVN, SANW, OPK, and CMTL.
- OSMT's SEC filings can be seen here. And to visit Osmotica Pharmaceuticals plc's official web site, go to www.osmotica.com.
OSMT Stock Price Chart Interactive Chart >
OSMT Price/Volume Stats
| Current price | $4.38 | 52-week high | $9.67 |
| Prev. close | $4.46 | 52-week low | $2.81 |
| Day low | $4.38 | Volume | 846 |
| Day high | $4.38 | Avg. volume | 487,690 |
| 50-day MA | $5.33 | Dividend yield | N/A |
| 200-day MA | $5.47 | Market Cap | 274.12M |
Osmotica Pharmaceuticals plc - Ordinary Shares (OSMT) Company Bio
Osmotica Pharmaceuticals Plc is a holding company engages in the development and commercialization of specialty products that target markets with underserved patient populations. It offers the M-72, Lorzone which is the chlorzoxazone scored tablets and ConZip which is tramadol hydrochloride extended-release capsules in specialty neurology; and OB Complete, which is the family of prescription prenatal dietary supplements, and Divigel in women's health. The company was founded on July 13, 2017 and is headquartered in Bridgewater, NJ.
OSMT Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $4.38 | $0.21 | -95% |
We started the process of determining a valid price forecast for Osmotica Pharmaceuticals plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Osmotica Pharmaceuticals plc ranked in the 8th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Osmotica Pharmaceuticals plc ended up being:
- Interest coverage, a measure of earnings relative to interest payments, is -2.22; that's higher than only 15.73% of US stocks in the Healthcare sector that have positive free cash flow.
- Its compound free cash flow growth rate, as measured over the past 2.11 years, is -0.31% -- higher than merely 5.08% of stocks in our DCF forecasting set.
- 56% of the company's capital comes from equity, which is greater than merely 24.6% of stocks in our cash flow based forecasting set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -95% |
| 1% | -95% |
| 2% | -95% |
| 3% | -95% |
| 4% | -95% |
| 5% | -95% |
Want more companies with a valuation profile/forecast similar to that of Osmotica Pharmaceuticals plc? See COO, NVST, TEVA, BHC, and EW.
Loading social stream, please wait...